370 related articles for article (PubMed ID: 33801246)
21. Docosahexaenoic acid and eicosapentaenoic acid reduce C-reactive protein expression and STAT3 activation in IL-6-treated HepG2 cells.
Wang TM; Hsieh SC; Chen JW; Chiang AN
Mol Cell Biochem; 2013 May; 377(1-2):97-106. PubMed ID: 23361365
[TBL] [Abstract][Full Text] [Related]
22. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
[TBL] [Abstract][Full Text] [Related]
23. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
24. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Pancreatic Carcinoma Growth Through Enhancing ω-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase.
Xia R; Sun L; Liao J; Li H; You X; Xu D; Yang J; Hwang SH; Jones RD; Hammock B; Yang GY
Anticancer Res; 2019 Jul; 39(7):3651-3660. PubMed ID: 31262891
[TBL] [Abstract][Full Text] [Related]
26. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
27. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
28. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
29. Overall survival of pancreatic ductal adenocarcinoma is doubled by
Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
[No Abstract] [Full Text] [Related]
30. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
Terado T; Kim CJ; Ushio A; Minami K; Tambe Y; Kageyama S; Kawauchi A; Tsunoda T; Shirasawa S; Tanaka H; Inoue H
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35894141
[TBL] [Abstract][Full Text] [Related]
31. Unsaturated Fatty Acids Increase the Expression of Hepassocin through a Signal Transducer and Activator of Transcription 3-Dependent Pathway in HepG2 Cells.
Cheng KP; Ou HY; Hung HC; Li CH; Fan KC; Wu JS; Wu HT; Chang CJ
Lipids; 2018 Sep; 53(9):863-869. PubMed ID: 30460699
[TBL] [Abstract][Full Text] [Related]
32. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
33. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
34. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
35. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
36. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
[TBL] [Abstract][Full Text] [Related]
37. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
Mi C; Cao X; Ma K; Wei M; Xu W; Lin Y; Zhang J; Wang TY
Chem Biol Interact; 2022 Jan; 351():109729. PubMed ID: 34717917
[TBL] [Abstract][Full Text] [Related]
38. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
39. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.
Bailey JM; Hendley AM; Lafaro KJ; Pruski MA; Jones NC; Alsina J; Younes M; Maitra A; McAllister F; Iacobuzio-Donahue CA; Leach SD
Oncogene; 2016 Aug; 35(32):4282-8. PubMed ID: 26592447
[TBL] [Abstract][Full Text] [Related]
40. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
